Treatment of Guillain-Barré Syndrome
Introduction to Treatment
- The American Academy of Neurology recommends intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 consecutive days as the first-line treatment for patients with Guillain-Barré Syndrome (GBS) who cannot walk unaided, and should be initiated as early as possible within 2 weeks of symptom onset 1, 2
First-Line Immunotherapy
- The American Academy of Neurology recommends a dose of 0.4 g/kg body weight daily for 5 consecutive days (total 2 g/kg) of IVIg, and to start as early as possible within 2 weeks of symptom onset 1, 3, 2
- IVIg is preferred over plasma exchange because it is easier to administer, more widely available, has higher completion rates, and better tolerability with fewer complications—particularly important in children and pregnant women 2
Respiratory Function Assessment
- Apply the "20/30/40 rule" immediately: patient is at imminent risk of respiratory failure if vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 3, 2, 4
- Perform single breath count: ≤19 predicts need for mechanical ventilation 2, 4
ICU Admission Criteria
- Admit to ICU if any of the following are present: evolving respiratory distress with imminent respiratory insufficiency 4, severe autonomic cardiovascular dysfunction 2, severe swallowing dysfunction or diminished cough reflex 2, rapid progression of weakness 4
Special Context: Immune Checkpoint Inhibitor-Related GBS
- For immune checkpoint inhibitor-related GBS, corticosteroids are recommended: methylprednisolone 2-4 mg/kg/day followed by slow taper 5, 6
- For grade 3-4 events: pulse methylprednisolone 1 g daily for 5 days along with IVIg or plasmapheresis 5, 6
Management of Treatment Failures and Fluctuations
- Treatment-related fluctuations (TRFs) occur in 6-10% of patients within 2 months of initial improvement, and represent disease reactivation while inflammatory phase continues 7, 3, 2
- Repeat the full course of IVIg or plasma exchange for TRFs, though evidence supporting this is limited 7, 3, 2
Ongoing Monitoring and Supportive Care
- Assess muscle strength using Medical Research Council grading scale, and document functional disability using GBS disability scale 3, 4
- Frequent neurological assessments are necessary 6, 3
Complication Prevention
- Do not use medications that worsen neuromuscular function, such as β-blockers 5, IV magnesium 4, fluoroquinolones 4, aminoglycosides 4, and macrolides 4
Rehabilitation
- Initiate early rehabilitation with multidisciplinary team including physiotherapists, occupational therapists, speech therapists, and dietitians 2
- Include range-of-motion exercises, stationary cycling, walking, and strength training, and monitor exercise intensity closely—overwork causes fatigue 7, 2